Literature DB >> 21346235

IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes.

Yan Zhou1, Yoshifumi Sonobe, Tomohiko Akahori, Shijie Jin, Jun Kawanokuchi, Mariko Noda, Yoichiro Iwakura, Tetsuya Mizuno, Akio Suzumura.   

Abstract

Newly discovered IL-9-producing helper T cells (Th9) reportedly exert both aggravating and suppressive roles on experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. However, it is still unclear whether Th9 is a distinct Th cell subset and how IL-9 functions in the CNS. In this study, we show that IL-9 is produced by naive CD4(+) T cells that were stimulated with anti-CD3 and anti-CD28 Abs under the conditions of Th2-, inducible regulatory T cell-, Th17-, and Th9-polarizing conditions and that IL-9 production is significantly suppressed in the absence of IL-4, suggesting that IL-4 is critical for the induction of IL-9 by each producing cell. The IL-9 receptor complex, IL-9R and IL-2Rγ, is constitutively expressed on astrocytes. IL-9 induces astrocytes to produce CCL-20 but not other chemokines, including CCL-2, CCL-3, and CXCL-2 by astrocytes. The conditioned medium of IL-9-stimulated astrocytes induces Th17 cell migration in vitro, which is cancelled by adding anti-CCL-20 neutralizing Abs. Treating with anti-IL-9 neutralizing Abs attenuates experimental autoimmune encephalomyelitis, decreases the number of infiltrating Th17 cells, and reduces CCL-20 expression in astrocytes. These results suggest that IL-9 is produced by several Th cell subsets in the presence of IL-4 and induces CCL-20 production by astrocytes to induce the migration of Th17 cells into the CNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346235     DOI: 10.4049/jimmunol.1003307

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  [Th9 cells. Functionally important or just an epiphenomenon?].

Authors:  A Ramming; H Schulze-Koops; A Skapenko
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

Review 2.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Control of autoimmune CNS inflammation by astrocytes.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

4.  Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern.

Authors:  A Jafarzadeh; S Bagherzadeh; H A Ebrahimi; H Hajghani; M R Bazrafshani; A Khosravimashizi; M Nemati; F Gadari; A Sabahi; F Iranmanesh; M M Mohammadi; H Daneshvar
Journal:  J Mol Neurosci       Date:  2014-01-07       Impact factor: 3.444

Review 5.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

6.  Amazing IL-9: revealing a new function for an "old" cytokine.

Authors:  Edgar Schmitt; Tobias Bopp
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

7.  CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes.

Authors:  Yaping Yan; Xiaoli Ding; Ke Li; Bogoljub Ciric; Shuai Wu; Hui Xu; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

Review 8.  Th9 cells in the pathogenesis of EAE and multiple sclerosis.

Authors:  Wassim Elyaman; Samia J Khoury
Journal:  Semin Immunopathol       Date:  2016-11-14       Impact factor: 9.623

Review 9.  Interaction of astrocytes and T cells in physiological and pathological conditions.

Authors:  Luokun Xie; Shao-Hua Yang
Journal:  Brain Res       Date:  2015-03-23       Impact factor: 3.252

10.  Th9 cells promote antitumor immune responses in vivo.

Authors:  Yong Lu; Sungyoul Hong; Haiyan Li; Jungsun Park; Bangxing Hong; Lijuan Wang; Yuhuan Zheng; Zhiqiang Liu; Jingda Xu; Jin He; Jing Yang; Jianfei Qian; Qing Yi
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.